Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1626 1629
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19341379 | LOW-SORBING GLYBURIDE FORMULATION AND METHODS | Non-Final OA | REMEDY PHARMACEUTICALS, INC. |
| 18551739 | "Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B" | Non-Final OA | Novartis AG |
| 18553271 | METHODS OF TREATMENT USING FUROSEMIDE | Non-Final OA | scPharmaceuticals Inc. |
| 18566929 | INHIBITORS OF TTBK1 | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18489603 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | Non-Final OA | Eli Lilly and Company |
| 18557346 | MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS INHIBITORS OF MCL-1 | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18041179 | PROTEASOME ENHANCERS AND USES THEREOF | Final Rejection | Board of Trustees of Michigan State University |
| 18575126 | VALBENAZINE FOR USE IN THE TREATMENT OF DYSKINESIA DUE TO CEREBRAL PALSY | Non-Final OA | Neurocrine Biosciences, Inc. |
| 18555194 | NOVEL MEPICIDES AS ANTIMICROBIAL AGENTS | Non-Final OA | GEORGE MASON UNIVERSITY |
| 18291809 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | Non-Final OA | The University of Manchester |
| 18575206 | KRAS G12D INHIBITOR AND USE THEREOF | Non-Final OA | SHANGHAI DE NOVO PHARMATECH CO., LTD. |
| 18009172 | HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Non-Final OA | IDEAYA BIOSCIENCES, INC. |
| 18027345 | METHOD FOR REFINING ACESULFAME POTASSIUM | Final Rejection | ANHUI JINHE INDUSTRIAL CO., LTD. |
| 18557691 | 19-NOR C3,3-DISUBSTITUTED C21 -N-PYRAZOLYL STEROID FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER AND POSTPARTUM DEPRESSION | Non-Final OA | Sage Therapeutics, Inc. |
| 18551894 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Non-Final OA | YUHAN CORPORATION |
| 18478060 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Non-Final OA | NeuroPn Therapeutics Inc. |
| 18263762 | METHODS AND COMPOSITIONS FOR CONTROLLING NEUROINFLAMMATION | Non-Final OA | Invenux, LLC |
| 18269301 | METHODS OF TREATING MULTIPLE SCLEROSIS | Non-Final OA | ASCENTAGE PHARMA GROUP CORP LIMITED |
| 18332476 | POLYMORPHS OF SUBSTITUTED ISOQUINOLINE-BASED RHO KINASE INHIBITORS | Non-Final OA | Neurelis, Inc. |
| 18041539 | COMPOUNDS, COMPOSITIONS AND METHODS | Non-Final OA | Tenvie Therapeutics, Inc. |
| 17918654 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Non-Final OA | VIIV HEALTHCARE UK (No. 5) LIMITED |
| 17617850 | SWELL1-LRRC8 COMPLEX MODULATORS | Final Rejection | Senseion Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy